- Home
- ZENA vs RAPT Comparison
ZENA vs RAPT Comparison
Compare ZENA & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZENA
- RAPT
- Stock Information
- Founded
- ZENA 2017
- RAPT 2015
- Country
- ZENA Canada
- RAPT United States
- Employees
- ZENA N/A
- RAPT N/A
- Industry
- ZENA
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- ZENA
- RAPT Health Care
- Exchange
- ZENA NYSE
- RAPT Nasdaq
- Market Cap
- ZENA 109.4M
- RAPT 122.9M
- IPO Year
- ZENA N/A
- RAPT 2019
- Fundamental
- Price
- ZENA $3.59
- RAPT $8.04
- Analyst Decision
- ZENA Strong Buy
- RAPT Buy
- Analyst Count
- ZENA 1
- RAPT 5
- Target Price
- ZENA $9.00
- RAPT $42.00
- AVG Volume (30 Days)
- ZENA 10.0M
- RAPT 109.8K
- Earning Date
- ZENA 01-01-0001
- RAPT 08-07-2025
- Dividend Yield
- ZENA N/A
- RAPT N/A
- EPS Growth
- ZENA N/A
- RAPT N/A
- EPS
- ZENA N/A
- RAPT N/A
- Revenue
- ZENA $1,744,794.00
- RAPT N/A
- Revenue This Year
- ZENA N/A
- RAPT N/A
- Revenue Next Year
- ZENA N/A
- RAPT N/A
- P/E Ratio
- ZENA N/A
- RAPT N/A
- Revenue Growth
- ZENA 24.50
- RAPT N/A
- 52 Week Low
- ZENA $1.41
- RAPT $5.67
- 52 Week High
- ZENA $12.43
- RAPT $30.60
- Technical
- Relative Strength Index (RSI)
- ZENA N/A
- RAPT 62.95
- Support Level
- ZENA N/A
- RAPT $7.04
- Resistance Level
- ZENA N/A
- RAPT $8.91
- Average True Range (ATR)
- ZENA 0.00
- RAPT 0.84
- MACD
- ZENA 0.00
- RAPT 0.08
- Stochastic Oscillator
- ZENA 0.00
- RAPT 92.53
About ZENA ZENATECH INC
ZenaTech Inc is a enterprise software technology company that specializes in mission-critical cloud-based applications integrated with smart hardware to deliver solutions across diverse industries. The company operates in software development technology, sales, and distribution. The company is also developing a drone manufacturing, sales, and distribution business. It generates revenue from software licensing and subscription agreements, software support and maintenance, and technology consulting services.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.